AU2018385364B2 - C5aR inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain - Google Patents

C5aR inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain Download PDF

Info

Publication number
AU2018385364B2
AU2018385364B2 AU2018385364A AU2018385364A AU2018385364B2 AU 2018385364 B2 AU2018385364 B2 AU 2018385364B2 AU 2018385364 A AU2018385364 A AU 2018385364A AU 2018385364 A AU2018385364 A AU 2018385364A AU 2018385364 B2 AU2018385364 B2 AU 2018385364B2
Authority
AU
Australia
Prior art keywords
phenyl
group
ethyl
alkyl
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018385364A
Other languages
English (en)
Other versions
AU2018385364A1 (en
Inventor
Marcello Allegretti
Andrea Aramini
Gianluca Bianchini
Laura Brandolini
Thiago Mattar CUNHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of AU2018385364A1 publication Critical patent/AU2018385364A1/en
Application granted granted Critical
Publication of AU2018385364B2 publication Critical patent/AU2018385364B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018385364A 2017-12-12 2018-12-11 C5aR inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain Active AU2018385364B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17206813.2A EP3498269A1 (en) 2017-12-12 2017-12-12 C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
EP17206813.2 2017-12-12
PCT/EP2018/084277 WO2019115493A2 (en) 2017-12-12 2018-12-11 C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Publications (2)

Publication Number Publication Date
AU2018385364A1 AU2018385364A1 (en) 2020-07-09
AU2018385364B2 true AU2018385364B2 (en) 2024-04-04

Family

ID=60673204

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018385364A Active AU2018385364B2 (en) 2017-12-12 2018-12-11 C5aR inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Country Status (13)

Country Link
US (2) US12102607B2 (https=)
EP (3) EP3498269A1 (https=)
JP (2) JP7430141B2 (https=)
KR (2) KR20250041193A (https=)
CN (1) CN111511363A (https=)
AU (1) AU2018385364B2 (https=)
BR (1) BR112020009972A2 (https=)
CA (1) CA3082762A1 (https=)
IL (1) IL275132A (https=)
MA (1) MA51128A (https=)
RU (1) RU2020122678A (https=)
SG (1) SG11202004322VA (https=)
WO (1) WO2019115493A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
BR112023018826A2 (pt) * 2021-03-17 2024-03-12 Dompe Farm Spa Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos
EP4397306A1 (en) * 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124664A1 (en) * 2005-11-24 2009-05-14 Marcello Allegretti (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them
US20100249198A1 (en) * 2007-10-18 2010-09-30 Dompe S.P.A (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1776336T3 (pl) * 2004-03-23 2010-06-30 Dompe Farm Spa Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne
HRP20151052T1 (xx) 2007-07-19 2015-11-06 H. Lundbeck A/S Peteroäślani heterocikliäśki amidi i srodne tvari
EP3192504A1 (en) * 2016-01-15 2017-07-19 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
PL3402474T3 (pl) * 2016-01-15 2021-12-27 Dompé Farmaceutici S.P.A. Inhibitory il-8 do zastosowania w leczeniu wywołanej chemioterapią neuropatii obwodowej

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124664A1 (en) * 2005-11-24 2009-05-14 Marcello Allegretti (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them
US20100249198A1 (en) * 2007-10-18 2010-09-30 Dompe S.P.A (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIJUN XU: "A2227. Role of Complement in Paclitaxel-induced Peripheral Neuropathy", ASA ABSTRACTS, 22 October 2017,Retrieved from the Internet <URL:http://www.asaabstracts.com/strands/asaabstracts/abstract.htm?year=2017. *

Also Published As

Publication number Publication date
RU2020122678A3 (https=) 2022-02-15
BR112020009972A2 (pt) 2021-02-09
MA51128A (fr) 2021-03-24
KR20200108839A (ko) 2020-09-21
IL275132A (en) 2020-07-30
KR20250041193A (ko) 2025-03-25
CA3082762A1 (en) 2019-06-20
EP3498269A1 (en) 2019-06-19
EP3723744C0 (en) 2026-03-18
EP4706762A2 (en) 2026-03-11
US20240398731A1 (en) 2024-12-05
JP2024028984A (ja) 2024-03-05
RU2020122678A (ru) 2022-01-13
US12102607B2 (en) 2024-10-01
EP3723744A2 (en) 2020-10-21
JP2021505647A (ja) 2021-02-18
EP3723744B1 (en) 2026-03-18
WO2019115493A3 (en) 2019-07-25
JP7430141B2 (ja) 2024-02-09
SG11202004322VA (en) 2020-07-29
WO2019115493A2 (en) 2019-06-20
US20200397725A1 (en) 2020-12-24
CN111511363A (zh) 2020-08-07
AU2018385364A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
US20240398731A1 (en) C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
Yoo et al. Neuroprotective action of N-acetyl serotonin in oxidative stress-induced apoptosis through the activation of both TrkB/CREB/BDNF pathway and Akt/Nrf2/Antioxidant enzyme in neuronal cells
JP6861764B2 (ja) 軸索再生および神経機能を促進するための方法および組成物
Luszczki et al. Characterization and preliminary anticonvulsant assessment of some 1, 3, 4-thiadiazole derivatives
Xiong et al. Secreted amyloid precursor protein-alpha can restore novel object location memory and hippocampal LTP in aged rats
US20220184075A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
RS66727B1 (sr) Kombinacija dasatiniba i adagrasiba za primenu u lečenju nesitnoćelijskog kancera pluća
JPWO2010087315A1 (ja) 抗アルツハイマー病剤
Zhelev et al. From Roscovitine to CYC202 to Seliciclib–from bench to bedside: discovery and development
CN102802621A (zh) 用于增强真皮细胞的毛原性能力的方法和组合物
US12606546B2 (en) Small molecule inhibitors of calcium channel activity and uses thereof
US20050182125A1 (en) Pyrrole compounds and uses thereof
JP7097613B2 (ja) 疼痛治療のためのアルファ－チューブリンアセチル化の阻害剤
US20210137898A1 (en) Methods to treat gliomas using a stat3 inhibitor
EP3192504A1 (en) Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
US20250221976A1 (en) Compounds, compositions and methods of treating neuropathic pain
US10517917B2 (en) Compositions and methods for preventing or treating pulmonary hypertension
Vohra et al. Rock inhibitors: Future of antiglaucoma medication
US12486257B2 (en) Small molecule inhibitors of CaV3.2 activity and uses thereof
Yang et al. Evaluating the neuroprotective effects of the novel Kv2. 1 blocker Zj7923 against ischemic stroke in vitro and in vivo
Chen et al. TPEN attenuates amyloid-β 25–
KR20220110518A (ko) 치매 환자의 행동 및 심리적 증상 치료
Stover Dinaciclib Inhibits Glioblastoma Multiforme Cell Growth and Selects for a Brain Tumour Initiating Cell Population
Kubo et al. Yoshiyuki Hirata1, 2, Tsutomu Sasaki3, Hideaki Kanki3, Chi-Jing Choong3, Kumiko Nishiyama3
Baptista-de-Souzaa et al. Neurobiology of Pain

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)